Form 8-K GILEAD SCIENCES INC For: Apr 30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 30, 2019
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
DELAWARE |
|
0-19731 |
|
94-3047598 |
(State or other jurisdiction of |
|
(Commission |
|
(I.R.S. Employer |
333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA
(Address of principal executive offices)
94404
(Zip Code)
(650) 574-3000
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Section 5 - CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(b) Departure of Certain Officers
On April 30, 2019, Gilead Sciences, Inc., a Delaware corporation (the Company), announced that Robin Washington plans to retire from her position as the Companys Executive Vice President and Chief Financial Officer, effective March 1, 2020, or if earlier, when a successor is named and commences in the role. Should a successor be named and commences in the role prior to March 1, 2020, Ms. Washington has agreed to remain in an advisory capacity through the completion of the Companys reporting of 2019 financial results.
SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit |
|
Description |
|
|
|
99.1 |
|
Press Release, issued by Gilead Sciences, Inc. on April 30, 2019. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
GILEAD SCIENCES, INC. |
|
(Registrant) |
|
|
|
/s/ Brett A. Pletcher |
|
|
|
Brett A. Pletcher |
|
EVP, General Counsel and Corporate Secretary |
|
|
|
|
Date: May 1, 2019 |
|
|
|
CONTACTS: |
Sung Lee, Investors |
|
|
|
(650) 524-7792 |
|
|
|
|
|
|
|
Amy Flood, Media |
|
|
|
(650) 522-5643 |
For Immediate Release
GILEAD SCIENCES CHIEF FINANCIAL OFFICER ROBIN WASHINGTON
TO STEP DOWN IN EARLY 2020
Foster City, Calif., April 30, 2019 Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Robin Washington, Executive Vice President (EVP) and Chief Financial Officer (CFO), plans to retire from her role, effective March 1, 2020.
Ms. Washington will continue as EVP and CFO while the company works to identify a successor. Should a CFO be named before March 1, 2020, Ms. Washington has agreed to remain in an advisory capacity through the completion of the companys reporting of 2019 financial results to ensure a smooth transition.
During my short time here, I have been impressed with the strategic expertise that Robin brings to her role and the dedication she has for our mission and the patients we serve. It is equally clear that she has built a strong team across the organizations she leads, said Daniel ODay, Chairman and Chief Executive Officer. Robin is an outstanding leader and it comes as no surprise that she has agreed to remain with Gilead through the completion of the companys reporting of 2019 financial results.
Ms. Washington joined Gilead in 2008 and is currently responsible for leading the companys finance, investor relations, facilities and operations, and information technology organizations. Ms. Washington also is a Board Director for Honeywell Inc., Salesforce.com and, this afternoon, was named to Alphabet Inc.s Board of Directors.
It has been my great honor to serve as Gileads CFO for more than 10 years, and to work alongside the talented team we have in place across our CFO organization and Gilead at large. Together, weve played a role in the important work this company does to deliver ground-breaking treatment advances to people all over the world, said Ms. Washington. I am committed to working with Dan, the rest of the leadership team and my colleagues over the coming months to ensure that this transition process is a seamless one.
As previously announced, Gilead is reporting first quarter 2019 earnings results on May 2, 2019.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA phone 650 574 3000 facsimile 650 578 9264 |
www.gilead.com
|
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. These risks, including the risk that Ms. Washington may leave prior to the currently anticipated timeline, and other factors could cause actual events to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gileads Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
# # #
For more information about Gilead, please visit the companys website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.